Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR3005-1
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR3005-1 is an investigational small molecule drug developed as a component of a combination therapy for the treatment of type 2 diabetes mellitus. It is studied in clinical trials alongside BR3005 and BR3005-2, with the primary objective to compare the pharmacokinetics and safety between fixed-dose combination administration (BR3005) and co-administration of its individual components (BR3005-1 and BR3005-2) in healthy adult volunteers under both fasting and fed conditions. The specific mechanism of action, molecular target, or active ingredient for BR3005-1 has not been disclosed publicly. The development is led by Boryung Pharmaceutical Co., Ltd[1][2][3][4].
- Other names
- BR3005-1BR-3005-1BR 3005-1
Beyond the preview
Go deeper on BR3005-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR3005-1.